How can we improve on current risk stratification in MDS?

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MDS Hub spoke to Uwe Platzbecker, University of...

Results from the phase II P-2001 study on pevonedistat plus azacytidine for high-risk MDS

To further explore the clinical efficacy and safety of pevo in patients with high-risk MDS, CMML, or low-blast...

What is the clinical impact of DDX41 mutations in myeloid neoplasms?

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MDS Hub spoke to Yasushi Miyazaki, Nagasaki...

Should the telomerase inhibitor imetelstat become SoC in transfusion-dependent low-risk MDS?

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MDS Hub spoke to...

What are the challenges in diagnosing MDS?

During the 2020 Annual Meeting of the Society of Hematologic Oncology (SOHO), the MDS Hub spoke to Aziz Nazha, Cleveland Clinic, Cleveland, US. We asked:...

Targeted therapeutics in MDS – what’s the current state of play?

During the 2020 Annual Meeting of the Society of Hematologic Oncology (SOHO), the MDS Hub podcast channel spoke to Dr David Sallman,...

Inherited hematologic malignancies predisposition syndromes

Hereditary predispositions to hematologic malignancies occur in approximately 5─10% of cases. During the Society of Hematologic...

The spectrum of clonal hematopoiesis

Clonal hematopoiesis (CH) describes the growth of a sub-population of blood cells that have at least one somatic mutation, leading to a greater risk of...

How can we improve on current risk stratification in MDS?

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MDS Hub spoke to Uwe Platzbecker, University of...

What is the clinical impact of DDX41 mutations in myeloid neoplasms?

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MDS Hub spoke to Yasushi Miyazaki, Nagasaki...

Eprenetapopt with azacytidine did not significantly improve CR rates in TP53-mutated MDS

Phase III trial of eprenetapopt (APR-246) with azacytidine had not met its primary endpoint: the CR rates in...

TP53 allelic state has implications in MDS in terms of genomic stability, clinical presentation, and outcomes

Elsa Bernard and colleagues published in Nature Medicine in October 2020 how different...